Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.788 USD | +3.66% | -7.50% | -24.95% |
Jun. 05 | Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call | |
Jun. 03 | Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 45.01M |
---|---|---|---|---|---|
Net income 2022 | -51M | Net income 2023 | -31M | EV / Sales 2022 | - |
Net cash position 2022 | 89.73M | Net cash position 2023 | 61.24M | EV / Sales 2023 | - |
P/E ratio 2022 |
-0.41
x | P/E ratio 2023 |
-1.25
x | Employees | 32 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 86.8% |
Latest transcript on Quince Therapeutics, Inc.
1 day | +3.66% | ||
1 week | -7.50% | ||
Current month | -5.06% | ||
1 month | -17.05% | ||
3 months | -32.65% | ||
6 months | -21.20% | ||
Current year | -24.95% |
Managers | Title | Age | Since |
---|---|---|---|
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Brendan Hannah
DFI | Director of Finance/CFO | 39 | 22-04-30 |
Charles Ryan
PSD | President | 59 | 23-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Una Ryan
BRD | Director/Board Member | 82 | 18-02-28 |
Luca Benatti
BRD | Director/Board Member | 63 | 23-10-22 |
Dirk Thye
CEO | Chief Executive Officer | 54 | 22-05-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-11 | 0.788 | +3.66% | 22,980 |
24-06-10 | 0.7602 | -3.77% | 30,365 |
24-06-07 | 0.79 | -5.99% | 332,713 |
24-06-06 | 0.8403 | +2.48% | 84,482 |
24-06-05 | 0.82 | -3.74% | 235,781 |
Delayed Quote Nasdaq, June 11, 2024 at 04:00 pm EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.95% | 32.85M | |
+49.21% | 56.95B | |
+39.98% | 40.26B | |
-6.86% | 39.32B | |
-4.42% | 28.37B | |
+12.00% | 26.45B | |
-18.27% | 19.41B | |
+29.57% | 12.54B | |
+25.41% | 12.21B | |
-0.35% | 12.15B |
- Stock Market
- Equities
- QNCX Stock